Anthropic’s life sciences division has released a detailed update on its efforts to integrate Claude into the drug discovery pipeline, moving beyond theoretical potential to report specific, measurable outcomes. Over the past several months, the company partnered with six organizations—including Generate Biomedicines, Divergence Labs, and Bristol Myers Squibb—to address distributed bottlenecks in medical research. The report emphasizes that AI acceleration is not limited to molecular design but extends to manufacturing, regulatory filings, and clinical trial planning, with early results suggesting significant efficiency gains in preclinical stages.

Generate Biomedicines and Divergence Labs: Molecular Innovation

Generate Biomedicines utilized Claude Code to reengineer CAR T-cell therapy for solid tumors. By proposing a genetic instruction segment 70% shorter than the standard version, the team achieved a design that allowed immune cells to produce roughly 10 times as many receptors and kill tumor cells more efficiently. Meanwhile, Divergence Labs focused on treating food allergies by targeting IgE molecules. Claude generated approximately 35,000 antibody designs in one month, leading to the identification of three designs that bound to IgE and 20 that successfully dislodged it, with three outperforming standard medications in early tests.

BigHat Biosciences and Enveda: Optimization and Compliance

BigHat Biosciences combined AI with automated lab testing to improve drug leads. After testing about 1,010 variants, the best versions bound more than 10 times more tightly to targets, while a cancer-targeting lead showed improved stability at 18°C higher temperatures. In parallel, Enveda addressed administrative bottlenecks by connecting manufacturing documents to Claude. The AI caught all 11 issues identified by human reviewers and flagged seven additional problems across 1,061 pages, reducing human review time by 89%. Claude also drafted two regulatory documents, one in four hours compared to the three months typically required by hand.

Clinical Trials and Internal Programs

The Column Group is leveraging Claude to reduce the operational overhead of biotechnology startups, establishing Pleiades to manage complex drug programs. Bristol Myers Squibb is using Claude to analyze proprietary data and estimate the likelihood of clinical trial success, a task that previously took days but can now be initiated with a single prompt. Additionally, Anthropic acquired Mithril Medicine, where founder Cody Tranbarger used Claude to organize contracts and logistics, taking a treatment for rare muscular dystrophy from idea to promising mouse results in less than 18 months.

Key Takeaways

  • Claude significantly accelerated molecular design, yielding 10x receptor increases in CAR T-cell therapy and identifying effective antibody designs for food allergies.
  • Administrative efficiency saw dramatic improvements, with Claude reducing regulatory document drafting time from months to hours and cutting manufacturing review time by 89%.
  • Anthropic is expanding its role from research partnerships to internal drug discovery programs, aiming for human clinical trials as early as late 2028.

The Bottom Line

Anthropic’s data proves that LLMs are no longer just theoretical aids but critical infrastructure capable of compressing the timeline for preclinical drug development by orders of magnitude.